- ISIN
- US88338N1072
- CUSIP
- 88338N107
- Sector
- Healthcare
- IPO Date
- Dec 11, 2003
Highlights
- Market Cap
- $23.50M
- Enterprise Value
- $19.90M
- EPS (TTM)
- $0.02
- PE Ratio
- 131.49
- PEG Ratio
- 0.15
- Total Revenue (TTM)
- $2.63M
- Gross Profit (TTM)
- $2.63M
- EBITDA (TTM)
- -$3.12M
- Year Range
- $0.99 - $2.95
- ROA (TTM)
- 0.48%
- ROE (TTM)
- 0.66%
- Avg. Volume (1M)
- 24K
- Avg. Volume Value (1M)
- $48.38K
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
TXMD Performance Chart
TherapeuticsMD, Inc. (TXMD) is up 24.5% since the beginning of the year. At $2 per share, TXMD is trading 31.2% below its 52-week high of $3. Investors who bought $1,000 worth of TXMD shares 5 years ago would now be looking at an investment worth $41.
Loading charts...
Compare this symbol against anything
Returns By Period
TherapeuticsMD, Inc. (TXMD) has returned 24.54% so far this year and 82.88% over the past 12 months. Over the last ten years, TXMD has returned -40.82% per year, falling short of the S&P 500 Index benchmark, which averaged 13.26% annually.
TherapeuticsMD, Inc.
- 1D
- 0.00%
- 1M
- -3.79%
- 6M
- -6.02%
- YTD
- 24.54%
- 1Y
- 82.88%
- 3Y*
- -20.95%
- 5Y*
- -47.31%
- 10Y*
- -40.82%
- ALL TIME*
- -14.05%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
TXMD Monthly Returns History
Based on dividend-adjusted daily data since Dec 11, 2003, TXMD's average daily return is +2.25%, while the average monthly return is +39.70%. At this rate, an investment would double in approximately 0.2 years.
Historically, 42% of months were positive and 58% were negative. The best month was Oct 2011 with a return of +9,900.0%, while the worst month was Aug 2009 at -86.7%. The longest winning streak lasted 12 consecutive months, and the longest losing streak was 9 months.
On a daily basis, TXMD closed higher 32% of trading days. The best single day was Oct 31, 2011 with a return of +9,900.0%, while the worst single day was Aug 24, 2009 at -86.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 32.52% | 4.63% | -10.62% | 0.99% | 4.90% | 3.27% | -8.14% | 24.54% | |||||
| 2025 | 25.58% | -13.89% | -0.54% | 34.05% | 17.74% | -20.55% | -3.45% | -0.89% | -3.15% | 10.70% | 42.86% | -4.12% | 89.53% |
| 2024 | 0.44% | 6.19% | -4.58% | -17.90% | 18.09% | -27.48% | 8.70% | 7.71% | -11.94% | -6.63% | -8.39% | -39.44% | -61.78% |
| 2023 | -5.72% | -5.88% | -24.40% | -5.60% | 17.23% | -0.72% | -1.46% | -6.65% | -20.32% | -29.47% | 21.13% | -12.79% | -59.75% |
| 2022 | -14.63% | -21.19% | 58.86% | -46.92% | -1.54% | 0.20% | -37.39% | 59.07% | -33.00% | -4.67% | -27.65% | 22.05% | -68.55% |
| 2021 | 36.36% | -7.88% | -11.84% | -9.70% | 0.00% | -1.65% | -15.97% | -20.50% | -6.74% | -1.81% | -32.01% | -28.18% | -70.62% |
Benchmark Metrics
TherapeuticsMD, Inc. has an annualized alpha of 34647.83%, beta of -2.44, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since December 11, 2003.
- This stock participated in 187.05% of S&P 500 Index downside but only 95.87% of its upside - more exposed to losses than it benefited from rallies.
- Beta of -2.44 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 34,647.83%
- Beta
- -2.44
- R²
- 0.00
- Upside Capture
- 95.87%
- Downside Capture
- 187.05%
Return for Risk
Risk / Return Rank
TXMD ranks 79 for risk / return — above 79% of stocks peers on PortfoliosLab. Its historical combined result is above most peers.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for TherapeuticsMD, Inc. (TXMD) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| TXMD | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.34 | ||
| Sortino ratioReturn per unit of downside risk | -0.05 | ||
| Omega ratioGain probability vs. loss probability | 1.27 | 1.25 | +0.02 |
| Calmar ratioReturn relative to maximum drawdown | 2.38 | 2.00 | +0.38 |
| Martin ratioReturn relative to average drawdown | 4.48 | 8.49 | -4.01 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the TherapeuticsMD, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the TherapeuticsMD, Inc. was 99.89%, occurring on Aug 24, 2011. Recovery took 546 trading sessions.
The current TherapeuticsMD, Inc. drawdown is 99.63%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-99.89%Aug 2011 | 2y 27d | 2y 2mo | 4y 3moJul 2009 - Oct 2013 | — |
-99.87%Mar 2025 | 9y 2mo | — | 10y 7moDec 2015 - now | 2025 selloff2025 |
-85.43%Feb 2008 | 11mo 22d | 1y 4mo | 2y 4moMar 2007 - Jul 2009 | Financial crisis2007–2009 |
-80.00%Jun 2004 | 5mo 15d | 25d | 6mo 10dDec 2003 - Jun 2004 | — |
-56.96%May 2014 | 1mo 20d | 1y 28d | 1y 2moMar 2014 - Jun 2015 | — |
Drawdown Indicators
| TXMD | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.89% | -56.78% | -43.11% |
Max Drawdown (1Y)Largest decline over 1 year | -34.30% | -9.10% | -25.20% |
Max Drawdown (3Y)Largest decline over 3 years | -82.98% | -18.90% | -64.08% |
Max Drawdown (5Y)Largest decline over 5 years | -98.52% | -25.43% | -73.09% |
Max Drawdown (10Y)Largest decline over 10 years | -99.82% | -33.92% | -65.90% |
Current DrawdownCurrent decline from peak | -99.63% | -1.58% | -98.05% |
Average DrawdownAverage peak-to-trough decline | -61.45% | -10.70% | -50.75% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 18.21% | 2.14% | +16.07% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of TherapeuticsMD, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how TherapeuticsMD, Inc. is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for TXMD, comparing it with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, TXMD has a P/E ratio of 131.5. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for TXMD compared to other companies in the Drug Manufacturers - Specialty & Generic industry. TXMD currently has a PEG ratio of 0.2. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for TXMD relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, TXMD has a P/S ratio of 9.0. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for TXMD in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, TXMD has a P/B value of 0.9. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with TXMD
Add TherapeuticsMD, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with TXMD